Application of lactobacillus paracasei PC-01 in promoting absorption

Abstract

The invention provides an application of lactobacillus paracasei PC-01 in promoting absorption. The invention provides application of the lactobacillus paracasei PC-01 or a fermentation product of the lactobacillus paracasei PC-01 in promoting absorption or preparing food for promoting absorption, and the lactobacillus paracasei PC-01 is the lactobacillus paracasei PC-01 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.17537. The invention further provides application of the lactobacillus paracasei PC-01 and the fermentation product of the lactobacillus paracasei PC-01. The invention also provides an application of the food in promoting absorption or preparing a substance for promoting absorption. The invention also provides an application of the Lactobacillus paracasei PC-01 or the fermentation product thereof in preparation of drugs for promoting absorption and treating or preventing absorption disorder diseases.

Description

Technical Field

[0001] This invention belongs to the field of probiotics, and more specifically, this invention relates to the application of Lactobacillus paracasei PC-01 in promoting absorption. Background Technology

[0002] Promoting absorption is crucial for human health, serving as a core element in maintaining life activities and physiological functions. Good absorption is the cornerstone of good health; only with sufficient energy and raw materials can the body's organs function properly. Insufficient nutrient supply can lead to various health problems such as anemia, osteoporosis, and weakened immunity. For special populations such as the elderly, children, or post-operative patients, promoting absorption is even more critical for accelerating recovery and ensuring growth and development, directly impacting quality of life and healthy lifespan.

[0003] Probiotics are live microorganisms that, when ingested in sufficient quantities, can produce beneficial effects on the host's health. They have functions such as regulating gut microbiota, improving constipation, and relieving diarrhea, but research on their role in promoting nutrient absorption is limited. Patent CN117568244A mentions a probiotic agent that enhances nutrient absorption, its composition including *Lactobacillus fermentum* with accession number CGMCC No. 24476. Lactobacillus leaven The LF54 strain was used; however, its effectiveness still needs further improvement. Summary of the Invention

[0004] The purpose of this invention is to provide an application of Lactobacillus paracasei PC-01 to promote absorption.

[0005] In a first aspect, the present invention provides the use of Lactobacillus paracasei PC-01 or its fermentation product in promoting absorption or in the preparation of food for promoting absorption, wherein the Lactobacillus paracasei PC-01 is Lactobacillus paracasei PC-01 with accession number CGMCC No. 17537.

[0006] In one or more embodiments, the fermentation product of *Lactobacillus paracasei* PC-01 is the fermentation broth, concentrate, supernatant, filtrate, dilution, precipitate, or lyophilized powder of *Lactobacillus paracasei* PC-01 with accession number CGMCC No. 17537.

[0007] In one or more embodiments, the food includes finished food products, semi-finished food products, food additives, and food supplements.

[0008] In one or more embodiments, the food also includes food science acceptable materials.

[0009] In one or more embodiments, the food-grade acceptable materials include: food ingredients or their processed products, nutritional additives, food-medicine homologous ingredients, excipients and / or auxiliary materials.

[0010] In one or more embodiments, the food is a dairy product.

[0011] In one or more embodiments, the food is a lactic acid bacteria product.

[0012] In one or more embodiments, the food is a lactic acid bacteria beverage.

[0013] In one or more embodiments, the food further includes one or more of the following: raw milk, whey protein powder, whey powder, α-lactalbumin, β-lactalbumin, lactoferrin, milk fat globule membrane protein, lactose, galactose, oligosaccharides, dietary fiber, prebiotics, calcium, iron, phosphorus, zinc, vitamins, and nervonic acid.

[0014] In one or more embodiments, the absorption enhancement includes enhancing the absorption of calcium ions, amino acids, and / or vitamins.

[0015] In one or more embodiments, the amino acid includes glycine, serine, proline, and / or the vitamin includes vitamin B5 and vitamin D2.

[0016] A second aspect of the present invention provides the use of a food in promoting absorption or in the preparation of a substance for promoting absorption, wherein the health food comprises Lactobacillus paracasei PC-01 or its fermentation product with preservation number CGMCC No. 17537.

[0017] In one or more embodiments, the fermentation product of *Lactobacillus paracasei* PC-01 is the fermentation broth, concentrate, supernatant, filtrate, dilution, precipitate, or lyophilized powder of *Lactobacillus paracasei* PC-01 with accession number CGMCC No. 17537.

[0018] In one or more embodiments, the food is as described in any embodiment of the present invention.

[0019] In one or more embodiments, the enhanced absorption is as described in any embodiment of the present invention.

[0020] A third aspect of the present invention provides the use of *Lactobacillus paracasei* PC-01 or its fermentation product in the preparation of a medicament for promoting absorption, treating or preventing malabsorption disorders, wherein the *Lactobacillus paracasei* PC-01 is *Lactobacillus paracasei* PC-01 with accession number CGMCC No. 17537.

[0021] In one or more embodiments, the fermentation product of *Lactobacillus paracasei* PC-01 is the fermentation broth, concentrate, supernatant, filtrate, dilution, precipitate, or lyophilized powder of *Lactobacillus paracasei* PC-01 with accession number CGMCC No. 17537.

[0022] In one or more embodiments, the drug comprises an effective amount of Lactobacillus paracasei PC-01 and a pharmaceutically acceptable carrier.

[0023] In one or more embodiments, the enhanced absorption is as described in any embodiment of the present invention.

[0024] In one or more embodiments, the treatment or prevention of malabsorption disorders includes promoting the absorption of calcium ions, amino acids, and / or vitamins.

[0025] In one or more embodiments, the amino acid includes glycine, serine, proline, and / or the vitamin includes vitamin B5 and vitamin D2.

[0026] In one or more embodiments, the malabsorption disorder includes: slowed intestinal motility, insufficient intestinal secretion, retention of intestinal contents, constipation, and difficulty in defecation.

[0027] Other aspects of the invention will be apparent to those skilled in the art from the disclosure herein. Detailed Implementation

[0028] Through in-depth research, the inventors discovered that *Lactobacillus paracasei* PC-01 has excellent gastric acid tolerance. Administering *Lactobacillus paracasei* PC-01 or lactic acid bacteria beverages containing it to experimental mice significantly increases serum calcium ion levels and promotes the absorption of amino acids (especially glycine, serine, and proline) and vitamins (especially vitamin B5 and vitamin D2). Furthermore, its effect on promoting nutrient absorption is significantly superior to that of *Lactobacillus fermentum* LF54, which has the existing preservation number CGMCC No. 24476.

[0029] the term

[0030] Unless otherwise indicated or defined, all terms used have their ordinary meaning in the art as would be understood by those skilled in the art. Furthermore, unless otherwise stated, all methods, steps, techniques, and operations not specifically detailed herein can and have been performed in a manner known per se as would be understood by those skilled in the art.

[0031] In this document, the terms “contains,” “includes,” “containing,” and similar terms encompass the meanings of “basically composed of” and “composed of.” For example, when this document discloses “A contains B and C,” “A is basically composed of B and C” and “A is composed of B and C” should be considered as having been disclosed in this document.

[0032] In this document, all features defined in the form of numerical ranges or percentage ranges, such as numerical values, quantities, contents, and concentrations, are for the sake of brevity and convenience only. Accordingly, descriptions of numerical ranges or percentage ranges should be considered as covering and specifically disclosing all possible sub-ranges and individual numerical values ​​(including integers and fractions) within those ranges.

[0033] Unless otherwise specified, percentages refer to mass percentages and proportions refer to mass ratios in this article.

[0034] In this document, when describing embodiments or examples, it should be understood that it is not intended to limit the invention to those embodiments or examples. Rather, all alternatives, modifications, and equivalents of the methods and materials described herein are covered within the scope defined by the claims.

[0035] For the sake of brevity, not all possible combinations of the technical features in each implementation scheme or embodiment are described herein. Therefore, as long as there is no contradiction in the combination of these technical features, the technical features in each implementation scheme or embodiment can be combined arbitrarily, and all possible combinations should be considered within the scope of this specification.

[0036] Lactobacillus paracasei PC-01

[0037] In this invention, *Lactobacillus paracasei* PC-01 refers to the Latin name... Lactobacillus cheese The strain, Lactobacillus paracasei PC-01, is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 17537. It was obtained commercially.

[0038] The present invention also provides fermentation products of *Lactobacillus paracasei* PC-01 with accession number CGMCC No. 17537. In some exemplary embodiments, the fermentation products of *Lactobacillus paracasei* PC-01 include fermentation broth obtained by fermenting *Lactobacillus paracasei* PC-01, and concentrates, supernatants, filtrates, diluents, precipitates, lyophilized powders, etc., obtained by further concentrating, centrifuging, filtering, ultrafiltration, dilution, and / or spray drying of the fermentation broth.

[0039] In this invention, the culture of *Lactobacillus paracasei*, well-known in the art, can be used to carry out the culture of *Lactobacillus paracasei* PC-01, thereby obtaining a culture of *Lactobacillus paracasei* PC-01. The culture of *Lactobacillus paracasei* PC-01 contains *Lactobacillus paracasei* PC-01 as described herein and a culture medium. The culture medium can be any commonly used culture medium for culturing *Lactobacillus paracasei* known in the art. Typically, a suitable culture medium for culturing *Lactobacillus paracasei* PC-01 contains a nitrogen source, a carbon source, vitamins, and minerals. A non-limiting example of a suitable culture medium for culturing *Lactobacillus paracasei* PC-01 is MRS medium. Preferably, this medium contains peptone, beef extract, yeast extract, glucose, triammonium citrate, sodium acetate, magnesium sulfate, manganese sulfate, Tween 80, etc.

[0040] In this invention, the fermentation method of *Lactobacillus paracasei*, well-known in the art, can be used to carry out the fermentation of the present invention. The fermentation broth produced by *Lactobacillus paracasei* PC-01 fermentation can be processed by steps such as concentration, centrifugation, filtration, ultrafiltration, and / or dilution to remove bacterial cells, obtaining a concentrate, supernatant, filtrate, or dilution. The concentrate, supernatant, filtrate, or dilution of *Lactobacillus paracasei* PC-01 can be further processed by steps such as precipitation and / or freeze-drying (e.g., spray drying) to obtain a precipitate or freeze-dried powder of *Lactobacillus paracasei* PC-01. Therefore, the fermentation product of *Lactobacillus paracasei* PC-01 can be the fermentation broth, concentrate, supernatant, filtrate, dilution, precipitate, or freeze-dried powder of *Lactobacillus paracasei* PC-01.

[0041] food

[0042] This invention provides the use of *Lactobacillus paracasei* PC-01 and its fermentation products, as described in any embodiment of the invention, in the preparation of foods for promoting absorption. This invention also provides a food comprising *Lactobacillus paracasei* PC-01 and its fermentation products, as described in any embodiment of the invention.

[0043] The term "food" refers to articles or substances that can be ingested by an individual, including finished food products, semi-finished food products, food additives, food supplements, and health foods (or functional foods, such as foods with absorption-promoting health functions). A food product can be formulated using standard techniques well known to those skilled in the art from *Lactobacillus paracasei* PC-01 and its fermentation products as described in this invention. For example, *Lactobacillus paracasei* PC-01 and its fermentation products can be directly added to a food-acceptable material, or it can be used to prepare an intermediate composition (e.g., a food additive or premix) suitable for subsequent addition to a food-acceptable material.

[0044] The term "food-acceptable material" refers to food ingredients or their processed products (e.g., raw milk, whey protein powder, whey powder, etc.), nutritional additives used in food (e.g., lactose, fructooligosaccharides, galactooligosaccharides, dietary fiber, prebiotics, proteins, lipids, minerals, vitamins, nucleotides, choline, taurine), medicinal and edible ingredients (e.g., jujubes, hawthorn, goji berries), excipients or adjuvants (e.g., calcium carbonate, calcium phosphate, various sugars, cellulose derivatives, gelatin, vegetable oils, polyethylene glycol), etc. The food products of this invention can be in any form suitable for oral administration, such as powders, tablets, capsules, granules, solutions, suspensions, etc.

[0045] In some embodiments, the food is a general food or a special food. In some embodiments, the special food is infant food, such as infant formula. The term "infant" as used in this invention includes infants and toddlers, generally referring to individuals aged 0-36 months. The term "infant" refers to individuals aged 0-12 months. The term "toddler" refers to individuals aged 12-36 months. As an example, the food may be a dairy product, such as a lactic acid bacteria product, more specifically, a lactic acid bacteria beverage. In some embodiments, the dairy product is an infant formula dairy product. Exemplarily, when the food is a dairy product (e.g., a lactic acid bacteria product, more specifically, a lactic acid bacteria beverage), in addition to *Lactobacillus paracasei* PC-01 and its fermentation products as described in this invention, the dairy product (e.g., a lactic acid bacteria product, more specifically, a lactic acid bacteria beverage) may also include proteins such as α-lactalbumin, β-lactalbumin, lactoferrin, milk fat globule membrane protein, carbohydrates such as lactose, galactose, oligosaccharides, lipids, minerals such as calcium, iron, phosphorus, zinc, vitamins, nervonic acid, etc. The food product can be produced using preparation methods commonly used in the art.

[0046] It should be understood that when added to the food, the content of *Lactobacillus paracasei* PC-01 and its fermentation products meets the requirements for strain content in the art. In some embodiments, the viable count of *Lactobacillus paracasei* PC-01 in the food may be 4.0 × 10⁻⁶. 8 CFU / mL(g) or higher, for example, 10 9 CFU / mL (g) or higher, 10 10 CFU / mL(g) or higher, 10 11 CFU / mL(g) or higher, 10 12 CFU / mL(g) or higher, 10 13 CFU / mL(g) or higher.

[0047] drug

[0048] This invention provides the use of *Lactobacillus paracasei* PC-01 and its fermentation products in the preparation of medicaments for promoting absorption, treating or preventing malabsorption disorders. This invention also provides medicaments comprising *Lactobacillus paracasei* PC-01 and its fermentation products. The medicaments may further include pharmaceutically acceptable carriers. The medicaments can be used to promote absorption, treat or prevent malabsorption disorders.

[0049] In this document, "pharmaceutically acceptable carriers" refer to carriers that do not significantly irritate the organism and do not impair the bioactivity and properties of the reagents in the pharmaceutical composition, such as, but not limited to: solvents, buffers, emulsifiers, suspending agents, decomposers, disintegrating agents, dispersing agents, binding agents, excipients, stabilizing agents, chelating agents, diluents, gelling agents, preservatives, wetting agents, lubricants, absorption delaying agents, or liposomes. In some embodiments, pharmaceutically acceptable carriers may be inert substances added to the pharmaceutical composition to further facilitate the administration of the reagents, such as calcium carbonate, calcium phosphate, various sugars and starches, cellulose derivatives, gelatin, vegetable oils, polyethylene glycol, etc.

[0050] The medicament of this invention can be formulated into any suitable dosage form for administration by oral or other routes. Suitable dosage forms for oral administration include, but are not limited to: sterile powder, tablet, troche, lozenge, pellet, capsule, dispersible powder or granule, solution, suspension, drop, emulsion, syrup, elixir, or slurry. The medicament of this invention can also be stored in sterile instruments suitable for injection or infusion. The *Lactobacillus paracasei* PC-01 and its fermentation products described in the medicament are generally present in an effective amount (e.g., a therapeutic effective amount, a preventative effective amount). An effective amount is a dosage sufficient to improve or in some way alleviate symptoms associated with a disease, such as effectively improving or eliminating one or more symptoms, and can be determined based on the subject's age, sex, physical condition, etc. The dosage may cure the disease, but administration is usually intended to improve the symptoms of the disease. Repeated administration is generally required to achieve the desired symptom improvement.

[0051] In a specific embodiment of the present invention, mice were used as experimental animals to propose a drug delivery regimen for *Lactobacillus paracasei* PC-01 and its fermentation products to promote absorption and treat or prevent malabsorption diseases. When mice were used as experimental animals, the viable count of *Lactobacillus paracasei* PC-01 could be 10-1. 9 CFU / mL or higher, for example, 10 9 ~10 10 CFU / mL, more specifically, 1×10 9 ~3×10 9 CFU / mL. When necessary, the *Lactobacillus paracasei* PC-01 and its fermentation products can also be administered in combination with other active ingredients or drugs.

[0052] In this invention, the treatment or prevention of malabsorption disorders includes, but is not limited to: increasing calcium ion levels, promoting the absorption of amino acids (including glycine, serine, and proline), and promoting the absorption of vitamins (including vitamin B5 and vitamin D2).

[0053] In this invention, the malabsorption syndromes refer to a group of diseases caused by impaired absorption, resulting in insufficient absorption of nutrients (such as amino acids and vitamins), leading to nutritional deficiencies and a series of clinical symptoms. These malabsorption syndromes include, but are not limited to, constipation and difficulty in defecation.

[0054] Application / Methods of Lactobacillus paracasei PC-01

[0055] This invention provides the use of *Lactobacillus paracasei* PC-01 and its fermentation products in promoting absorption or preparing foods (including dairy products, such as lactic acid bacteria products, more specifically, lactic acid bacteria beverages) that promote absorption. This invention also provides the use of *Lactobacillus paracasei* PC-01 and its fermentation products in preparing medicaments for promoting absorption, treating or preventing malabsorption disorders.

[0056] This invention provides a method for promoting absorption for non-therapeutic purposes, the method comprising using an effective amount of *Lactobacillus paracasei* PC-01 and its fermentation products or foods thereof (including dairy products, such as lactic acid bacteria products, more specifically, lactic acid bacteria beverages).

[0057] The present invention also provides the use of the aforementioned food products (including dairy products, such as lactic acid bacteria products, more specifically, lactic acid bacteria beverages) in promoting absorption for non-therapeutic purposes.

[0058] The present invention also provides the use of the said drug in the preparation of reagents for promoting absorption, treating or preventing malabsorption disorders.

[0059] The present invention also provides a method for treating or preventing malabsorption disorders, the method comprising: administering the Lactobacillus paracasei PC-01 and its fermentation products as described in the present invention to an individual in need, or administering the drug described in the present invention to an individual in need.

[0060] The present invention also provides a method for promoting absorption, the method comprising: giving the Lactobacillus paracasei PC-01 and its fermentation products, or food products thereof (including dairy products, such as lactic acid bacteria products, more specifically, lactic acid bacteria beverages) to an individual in need.

[0061] In this invention, the absorption-promoting effects include, but are not limited to: increasing calcium ion levels, promoting the absorption of amino acids (including glycine, serine, and proline), and promoting the absorption of vitamins (including vitamin B5 and vitamin D2).

[0062] In this invention, the treatment or prevention of malabsorption disorders includes, but is not limited to: increasing calcium ion levels, promoting the absorption of amino acids (including glycine, serine, and proline), and promoting the absorption of vitamins (including vitamin B5 and vitamin D2).

[0063] In this invention, malabsorption syndromes refer to a group of diseases caused by impaired absorption, resulting in insufficient absorption of nutrients (such as amino acids and vitamins), leading to nutritional deficiencies and a series of clinical symptoms. In some specific embodiments, the animal model of malabsorption syndrome is constructed using loperamide hydrochloride (LOP). LOP can inhibit intestinal peristalsis and secretion, prolonging the retention time of intestinal contents, thereby causing malabsorption. Therefore, malabsorption syndromes include, but are not limited to: slowed intestinal peristalsis, insufficient intestinal secretion, retention of intestinal contents, constipation, and difficulty in defecation.

[0064] In this invention, the methods described are typically non-therapeutic and non-diagnostic.

[0065] In this invention, "giving" can refer to introducing, providing, or delivering a substance to an individual through any suitable means to achieve its intended function.

[0066] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions or as recommended by the manufacturer.

[0067] In the following examples, *Lactobacillus paracasei* PC-01 (abbreviated as PC-01) refers to *Lactobacillus paracasei* with accession number CGMCC No. 17537. Lactobacillus paracasei PC-01, provided by Mengniu High-Tech Dairy Products (Beijing) Co., Ltd.

[0068] In the following examples, the PC-01 fermented lactic acid bacteria beverage is a commercially available product of Mengniu Youyi C, which can be purchased through commercial channels.

[0069] In the following examples, Lactobacillus fermentum LF54 powder (abbreviated as LF54) refers to Lactobacillus fermentum with accession number CGMCC No. 24476. Lactobacillus leaven LF54 strain, obtained through commercial purchase.

[0070] In the following examples, the MRS solution was purchased from Luqiao.

[0071] In the following examples, the HBSS solution was purchased from Thermo Fisher Scientific.

[0072] In the following examples, loperamide hydrochloride (LOP) was purchased from Xian Janssen Pharmaceutical Co., Ltd.

[0073] Example 1, Simulated Tolerance of Lactobacillus paracasei PC-01 in Artificial Gastric Juice

[0074] 1. Preparation of Bacterial Solution

[0075] Take out the Lactobacillus paracasei PC-01 strain from the cryogenic refrigerator and incubate it aerobically overnight at 37 °C in MRS medium (pH 6.5). Take the overnight bacterial solution for 10-fold dilution and incubate it aerobically overnight at 37 °C. Select the bacterial solution in the late logarithmic / early stationary phase according to the absorbance value at 600 nm. Centrifuge the bacterial solution at 6000×g for 2 min, wash it twice in HBSS solution, and then resuspend it in 10% MRS solution (pH 6.5).

[0076] Adjust the absorbance value of the 10% MRS bacterial solution to 1.0, centrifuge at 6000×g for 5 minutes, remove the supernatant, add the bacterial cells to the artificial gastric juice simulation solution (10% MRS, containing 3.2 mg / ml pepsin and 34 mM sodium chloride, adjust the pH to 2.5 with hydrochloric acid), incubate at 37 °C for 1 hour, and measure the viable cell count at 0 hour (initial) and 1 hour.

[0077] 2. Lactobacillus paracasei PC-01 Promotes Nutrient Absorption

[0078] The model animals used in the experiment were 6-week-old C57BL / 6J mice with a body weight range of 20±2 g. The experimental animals, maintenance feed, and mouse bedding were all purchased from Beijing SpeyFort Biotechnology Co., Ltd.

SCXK (Beijing) 2019-0010

temperature (22±2) °C, humidity (50±10)%

[0079] After 60 C57 mice were adaptively fed (-1 week to 0 week), they were randomly divided into 5 groups, with 12 mice in each group. Normal control group (NC group), model group (M group), PC-01 bacterial powder group (PC group), PC-01 fermented lactic acid bacteria beverage group (FPC group), and Lactobacillus fermentum LF54 bacterial powder group (LF54 group). All had free access to food and water during the experiment. The NC group and the M group were gavaged with normal saline (0 days - 28 days, 0.2 mL / day), the PC-01 group was gavaged with normal saline containing PC-01 viable bacteria (0 days - 28 days, 0.2 mL / day, PC-01 viable bacteria count 2×10 9 CFU / mL), and the FPC group was gavaged with PC-01 fermented lactic acid bacteria beverage (0 days - 28 days, 0.2 mL / day, PC-01 viable bacteria count 2×10 9CFU / mL), LF54 group was administered physiological saline containing live LF54 bacteria by gavage (days 0-28, 0.2 mL / day, LF54 live bacteria count 2×10⁻⁶). 9 (CFU / mL).

[0080] On day 28 of the experiment, four mice from each group were randomly selected, sacrificed, and their serum supernatant and colonic contents were collected. The remaining mice in each group were used to establish a mouse model using loperamide hydrochloride (LOP) (LOP's mechanism is to inhibit intestinal peristalsis and secretion, prolonging the retention time of intestinal contents). The intervention protocol was as follows: except for the NC group which was administered physiological saline (0.2 mL / day), all other groups were administered 0.1 mL of loperamide hydrochloride by gavage. One hour later, the M group was administered 0.2 mL of physiological saline by gavage, and the PC group was administered physiological saline containing live PC-01 bacteria (0.2 mL / day, PC-01 live bacteria count 2 × 10⁻⁶). 9 CFU / mL), FPC group was given PC-01 fermented milk beverage by gavage (0.2 mL / day, PC-01 viable bacteria count was 2×10). 9 CFU / mL), the LF54 group was administered physiological saline containing live LF54 bacteria by gavage (0.2 mL / day, LF54 live bacteria count 2 × 10⁻⁶). 9 (CFU / mL). On day 35 of the experiment, mice in each group were sacrificed and cecal contents and small intestinal tissue were collected. In this example, all data are expressed as mean ± standard deviation, and the significance level was set at 0.05.

[0081] 3. Experimental Results

[0082] (1) Results of gastric acid resistance test

[0083] After digestion in a simulated gastric juice (10% MRS containing 3.2 mg / ml pepsin and 34 mM sodium chloride, pH adjusted to 2.5 with hydrochloric acid) for 1 hour, the survival rate of Lactobacillus paracasei PC-01 was 99.9%.

[0084] Table 1. Number and survival rate of viable bacteria after digestion with simulated gastric juice

[0085] (2) Serum calcium ion content

[0086] After 35 days of intervention, serum calcium ions in C57 mice were measured, and the results are shown in Table 2. Compared with the normal control group (NC group) and the model group (M group), *Lactobacillus paracasei* PC-01 bacterial powder (PC-01 group) and its fermented milk beverage (FPC group) significantly increased serum calcium ion levels in mice. PThe difference was < 0.05, while there was no significant difference between the LF54 bacterial powder group (LF54 group) and the model group (M group) and the normal control group (NC group). This indicates that Lactobacillus paracasei PC-01 bacterial powder and its fermented milk beverage can promote calcium absorption, and the effect is better than that of Lactobacillus fermentum LF54.

[0087] Table 2. Serum calcium ion concentration

[0088] Note: @ indicates a significant difference from the NC group, and @ indicates a significant difference from the M group.

[0089] (3) Amino acid content in feces

[0090] After 28 days of intervention with *Lactobacillus paracasei* PC-01 active beverage or powder, the amino acid content in feces was measured, and the results are shown in Table 3. Compared with the normal control group (NC group), the total amino acid, glycine, serine, and proline content in both the *Lactobacillus paracasei* PC-01 active beverage group (FPC group) and the PC-01 powder group (PC-01 group) were significantly decreased. P < 0.05), there was no significant difference in alanine content between the LF54 bacterial powder group and the LF54 group, while the alanine content in the FPC, PC-01, and LF54 groups was not significantly different from that in the NC group. The results indicate that *Lactobacillus paracasei* PC-01 and its fermented milk beverage can promote amino acid absorption, with a stronger effect than *Lactobacillus fermentum* LF54, and the effect of the PC-01 fermented milk beverage is more significant.

[0091] Table 3. Amino acid content in feces

[0092] Note: The representative group showed a significant difference from the NC group.

[0093] (4) Vitamin content in feces

[0094] After 35 days of intervention with Lactobacillus paracasei PC-01 active beverage or powder, the vitamin content in feces was measured, and the results are shown in Table 4. Intervention with loperamide hydrochloride resulted in significantly lower vitamin D2 (VD2) content in mouse feces compared to the NC group. P < 0.05%, vitamin B5 (VB5) content was significantly lower than that in the NC group. After gavage administration of *Lactobacillus paracasei* PC-01 and its fermented milk beverage, the levels of vitamin B5 and vitamin D2 in mouse feces significantly increased ( ). P < 0.05). Therefore, Lactobacillus paracasei PC-01 and its fermented milk beverage can improve the decrease in vitamin content caused by loperamide hydrochloride in mice, increase vitamin levels, and the effect is better than that of Lactobacillus fermentum LF54.

[0095] Table 4. Vitamin content in feces

[0096] Note: The value ¥ represents a significant difference from the NC group, and the value ¥ represents a significant difference from the M group.

[0097] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the scope of protection of the present invention. Therefore, the scope of protection of this patent should be determined by the appended claims. Furthermore, all documents mentioned in this invention are incorporated herein by reference as if each document were individually incorporated by reference.

Claims

1. The application of *Lactobacillus paracasei* PC-01 or its fermentation products in promoting absorption or in the preparation of foods for promoting absorption, wherein, The *Lactobacillus paracasei* PC-01 is *Lactobacillus paracasei* PC-01 with accession number CGMCC No. 17537, and the absorption promotion includes promoting the absorption of calcium ions, amino acids and / or vitamins.

2. The application as described in claim 1, characterized in that, The fermentation products of *Lactobacillus paracasei* PC-01 are the fermentation broth, concentrate, supernatant, filtrate, dilution, precipitate, or lyophilized powder of *Lactobacillus paracasei* PC-01 with accession number CGMCC No. 17537.

3. The application as described in claim 1 or 2, characterized in that, The food products include finished food products, semi-finished food products, food additives, and food supplements.

4. The application as described in claim 3, characterized in that, The food also includes food science acceptable materials.

5. The application as described in claim 4, characterized in that, Food science acceptable materials include: food ingredients or their processed products, nutritional additives, food and medicinal ingredients, excipients and / or auxiliary materials.

6. The application as described in claim 3, characterized in that, The food product in question is a dairy product.

7. The application as described in claim 6, characterized in that, The food product in question is a lactic acid bacteria product.

8. The application as described in claim 7, characterized in that, The food product in question is a lactic acid bacteria beverage.

9. The application as described in claim 7 or 8, characterized in that, The food also includes one or more of the following: raw milk, whey protein powder, whey powder, α-lactalbumin, β-lactalbumin, lactoferrin, milk fat globule membrane protein, lactose, galactose, oligosaccharides, dietary fiber, prebiotics, calcium, iron, phosphorus, zinc, vitamins, and nervonic acid.

10. The application as described in claim 1 or 2, characterized in that, The amino acids include glycine, serine, proline, and / or the vitamins include vitamin B5 and vitamin D2.

11. The use of a food in promoting absorption or in the preparation of a substance for promoting absorption, wherein the food comprises Lactobacillus paracasei PC-01 or its fermentation product with preservation number CGMCC No. 17537, and the promoting absorption includes promoting the absorption of calcium ions, amino acids and / or vitamins.

12. The application as described in claim 11, characterized in that, The fermentation products of *Lactobacillus paracasei* PC-01 are the fermentation broth, concentrate, supernatant, filtrate, dilution, precipitate, or lyophilized powder of *Lactobacillus paracasei* PC-01 with accession number CGMCC No. 17537.

13. The application as described in claim 11 or 12, characterized in that, The food product is as defined in any one of claims 3-9.

14. The application as described in claim 11 or 12, characterized in that, The amino acids include glycine, serine, proline, and / or the vitamins include vitamin B5 and vitamin D2.

15. The use of *Lactobacillus paracasei* PC-01 or its fermentation products in the preparation of drugs for promoting absorption, treating or preventing malabsorption disorders, wherein, The *Lactobacillus paracasei* PC-01 is *Lactobacillus paracasei* PC-01 with accession number CGMCC No. 17537, and the absorption promotion includes promoting the absorption of calcium ions, amino acids and / or vitamins.

16. The application as described in claim 15, characterized in that, The fermentation products of *Lactobacillus paracasei* PC-01 are the fermentation broth, concentrate, supernatant, filtrate, dilution, precipitate, or lyophilized powder of *Lactobacillus paracasei* PC-01 with accession number CGMCC No. 17537.

17. The application as described in claim 15 or 16, characterized in that, The drug contains an effective amount of Lactobacillus paracasei PC-01 and a pharmaceutically acceptable carrier.

18. The application as described in claim 15 or 16, characterized in that, The amino acids include glycine, serine, proline, and / or the vitamins include vitamin B5 and vitamin D2.

19. The application as described in claim 15 or 16, characterized in that, The treatment or prevention of malabsorption disorders includes promoting the absorption of calcium ions, amino acids, and / or vitamins.

20. The application as described in claim 19, characterized in that, The amino acids include glycine, serine, proline, and / or the vitamins include vitamin B5 and vitamin D2.

Images